FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Medical Device Trial Design Guidance Out

[ Price : $8.95]

CDRH issues a guidance on considerations for study design in medical device pivotal studies.

Guidance on BE Recommendations for Iron Sucrose

[ Price : $8.95]

Federal Register Notice: FDA releases a draft guidance on bioequivalence recommendations for iron sucrose.

FDA Releases Additional Product-Specific BE Recs

[ Price : $8.95]

Federal Register Notice: FDA releases additional draft and revised draft product-specific bioequivalence recommendations to suppor...

CDRH Posts Proposed FY 14 Guidances

[ Price : $8.95]

Federal Register Notice: CDRH announces the Web site location for proposed fiscal year 2014 guidance documents.

FDA Approves W.L. Gore Viabahn Endoprosthesis

[ Price : $8.95]

FDA approves a W. L. Gore PMA for its 25 cm Gore Viabahn Endoprosthesis with Heparin Bioactive Surface for treating symptomatic pe...

Abbott Loses Bid to Move Humira Lawsuit to Federal Court

[ Price : $8.95]

A Maryland federal judge rules against Abbott in its request to move a Humira (adalimumab) personal injury lawsuit from state to f...

CBS News Profiles Ranbaxy Whistleblower

[ Price : $8.95]

CBS News profiles the Ranbaxy whistleblower to led FDA to find hundreds of data errors in ANDAs for more than 15 drugs.

510(k) Benefit-Risk Determinations Guidance Top Priority

[ Price : $8.95]

A new CDRH Web site places developing a draft guidance on Benefit-Risk Determinations in Premarket Notifications (510(k)s) as one ...

FDA Will Allow Continued Iclusig Use Under Emergency IND

[ Price : $8.95]

FDA says healthcare professionals may continue to treat some patients with Iclusig under an emergency IND.

FDA Recommends Steps to Counter Heparin Risk

[ Price : $8.95]

FDA gives healthcare professionals timing recommendations for placing and removing spinal catheters in patients taking low molecul...